GOSS Investor Alert: Gossamer Bio Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Allegedly Failing to Disclose Trial Risks: Levi & Korsinsky

Gossamer Bio (GOSS) shares plummeted over 80% on February 23, 2026, after the company disclosed that its Phase 3 PROSERA trial failed to meet its primary endpoint. A securities class action lawsuit has been filed alleging the company and its CEO made materially misleading statements about the trial design while concealing enrollment risks at Latin American sites. Investors who purchased GOSS securities between June 16, 2025 and February 20, 2026 can seek appointment as lead plaintiff by the June 1, 2026 deadline.